Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: The role of erythropoietin receptor

Neural Regeneration Research

Volumn 12, Issue 9, 2017, Pages 1381-1389

  Hernández, Carolina Castillo ^a   Burgos, Carlos Felipe ^a   Gajardo, Angela Hidalgo ^a   Silva Grecchi, Tiare ^a   Gavilan, Javiera ^a   Toledo, Jorge Roberto ^a   Fuentealba, Jorge ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Alzheimer s disease; Anti apoptosis; Erythropoietin; Erythropoietin receptor; Neuroprotection

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALTEPLASE; AMYLOID BETA PROTEIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN ISCHEMIA; COGNITION; DEGENERATIVE DISEASE; HUMAN; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 85032449114     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.215240     Document Type: Review

References (88)

1. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, Zhang M, Muller M, Hassouna I, Hannke K, Sperling S, Radyushkin K, El-Kordi A, Schulze L, Ronnenberg A, Wolf F, Brose N, Rhee JS, Zhang W, Ehrenreich H (2008) Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 6:37.
2. Arabpoor Z, Hamidi G, Rashidi B, Shabrang M, Alaei H, Sharifi MR, Salami M, Dolatabadi HR, Reisi P (2012) Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer’s disease. Adv Biomed Res 1:50.
3. Armand-Ugón M, Aso E, Moreno J, Riera-Codina M, Sánchez A, Vegas E, Ferrer I (2015) Memory improvement in the AbetaPP/PS1 mouse model of familial Alzheimer’s disease induced by carbamylated- erythropoietin is accompanied by modulation of synaptic genes. J Alzheimers Dis 45:407-421.
4. Assaraf MI, Diaz Z, Liberman A, Miller WH, Jr., Arvanitakis Z, Li Y, Bennett DA, Schipper HM (2007) Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol 66:389-398.
5. Batmunkh C, Krajewski J, Jelkmann W, Hellwig-Bürgel T (2006) Erythropoietin production: Molecular mechanisms of the antagonistic actions of cyclic adenosine monophosphate and interleukin-1. FEBS Lett 580:3153-3160.
6. Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484-494.
7. Brines M, Cerami A (2008) Erythropoietin-mediated tissue protection:reducing collateral damage from the primary injury response. J Intern Med 264:405-432.
8. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101:14907-14912.
9. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105:10925-10930.
10. Buendia I, Parada E, Navarro E, León R, Negredo P, Egea J, López MG (2016) Subthreshold concentrations of melatonin and galantamine improves pathological AD-hallmarks in hippocampal organotypic cultures. Mol Neurobiol 53:3338-3348.
11. Bunn HF (2013) Erythropoietin. Cold Spring Harb Perspect Med 3:a011619.
12. Castañeda-Arellano R, Feria-Velasco AI, Rivera-Cervantes MC (2014) Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats. Neurosci Lett 583:16-20.
13. Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS (1998) NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 5:861-866.
14. Chen J, Yang Z, Zhang X (2015) Carbamylated erythropoietin: a prospective drug candidate for neuroprotection. Biochem Insights 8:25-29.
15. Chong ZZ, Li F, Maiese K (2005) Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res 2:387-399.
16. Chong ZZ, Shang YC, Mu Y, Cui S, Yao Q, Maiese K (2013) Targeting erythropoietin for chronic neurodegenerative diseases. Expert Opin Ther Targets 17:707-720.
17. Ding J, Wang J, Li QY, Yu JZ, Ma CG, Wang X, Lu CZ, Xiao BG (2017) Neuroprotection and CD131/GDNF/AKT pathway of carbamylated erythropoietin in hypoxic neurons. Mol Neurobiol 54:5051-5060.
18. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jahnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, et al. (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40:e647-656.
19. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505.
20. Esmaeili Tazangi P, Moosavi SM, Shabani M, Haghani M (2015) Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer’s disease. Pharmacol Biochem Behav 130:15-21.
21. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1-14.
22. Gan Y, Xing J, Jing Z, Stetler RA, Zhang F, Luo Y, Ji X, Gao Y, Cao G (2012) Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury. Stroke 43:3071-3077.
23. Grupke S, Hall J, Dobbs M, Bix GJ, Fraser JF (2015) Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke:from review to preview. Clin Neurol Neurosurg 129:1-9.
24. Gui DM, Yang Y, Li X, Gao DW (2011) Effect of erythropoietin on the expression of HIF-1 and iNOS in retina in chronic ocular hypertension rats. Int J Ophthalmol 4:40-43.
25. Ingley E (2012) Integrating novel signaling pathways involved in erythropoiesis. IUBMB Life 64:402-410.
26. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J (2007) Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 38:2795-2803.
27. Iwai M, Stetler RA, Xing J, Hu X, Gao Y, Zhang W, Chen J, Cao G (2010) Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke 41:1032-1037.
28. Javadi M, Hofstatter E, Stickle N, Beattie BK, Jaster R, Carter-Su C, Barber DL (2012) The SH2B1 adaptor protein associates with a proximal region of the erythropoietin receptor. J Biol Chem 287:26223-26234.
29. Jelkmann W (2008) ‘O’, erythropoietin carbamoylation versus carbamylation. Nephrol Dial Transplant 23:3033; author reply 3033-3034.
30. Jelkmann W, Wagner K (2004) Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83:673-686.
31. Jia Y, Mo SJ, Feng QQ, Zhan ML, OuYang LS, Chen JC, Ma YX, Wu JJ, Lei WL (2014) EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson’s disease. J Mol Neurosci 53:117-124.
32. Jiang J, Tian F, Cai Y, Qian X, Costello CE, Ying W (2014) Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin. Anal Bioanal Chem 406:6265-6274.
33. Kumar A, Singh A, Ekavali (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 67:195-203.
34. Lappin TR, Maxwell AP, Johnston PG (2002) EPO’s alter ego: erythropoietin has multiple actions. Stem Cells 20:485-492.
35. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242.
36. Li YP, Yang GJ, Jin L, Yang HM, Chen J, Chai GS, Wang L (2015) Erythropoietin attenuates Alzheimer-like memory impairments and pathological changes induced by amyloid beta42 in mice. Brain Res 1618:159-167.
37. Liu X, Zhu B, Zou H, Hu D, Gu Q, Liu K, Xu X (2015) Carbamylated erythropoietin mediates retinal neuroprotection in streptozotocin- induced early-stage diabetic rats. Graefes Arch Clin Exp Ophthalmol 253:1263-1272.
38. Lodish H, Berk A, Kaiser CA, Krieger M, Bretscher A, Ploegh H, Amon A, Scott MP (2013) Molecular Cell Biology. 7th ed. New York: WH Freeman and Company.
39. Lourhmati A, Buniatian GH, Paul C, Verleysdonk S, Buecheler R, Buadze M, Proksch B, Schwab M, Gleiter CH, Danielyan L (2013) Age-dependent astroglial vulnerability to hypoxia and glutamate: the role for erythropoietin. PLoS One 8:e77182.
40. Lu J, Jiang L, Zhu H, Zhang L, Wang T (2014) Hypoxia-inducible factor-1alpha and erythropoietin expression in the hippocampus of neonatal rats following hypoxia-ischemia. J Nanosci Nanotechnol 14:5614-5619.
41. Ma R, Hu J, Huang C, Wang M, Xiang J, Li G (2014) JAK2/STAT5/BclxL signalling is essential for erythropoietin-mediated protection against apoptosis induced in PC12 cells by the amyloid beta-peptide Abeta25-35. Br J Pharmacol 171:3234-3245.
42. Ma R, Xiong N, Huang C, Tang Q, Hu B, Xiang J, Li G (2009) Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology 56:1027-1034.
43. Maiese K (2016a) Charting a course for erythropoietin in traumatic brain injury. J Transl Sci 2:140-144.
44. Maiese K (2016b) Regeneration in the nervous system with erythropoietin. Front Biosci (Landmark Ed) 21:561-596.
45. Maiese K, Li F, Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293:90-95.
46. Maiese K, Chong ZZ, Shang YC, Wang S (2012) Erythropoietin: new directions for the nervous system. Int J Mol Sci 13:11102-11129.
47. Masuda S, Kada E, Nagao M, Sasaki R (1999) In vitro neuroprotective action of recombinant rat erythropoietin produced by astrocyte cell lines and comparative studies with erythropoietin produced by Chinese hamster ovary cells. Cytotechnology 31:179-184.
48. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Jr., Tabira T, Sasaki R (1993) Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268:11208-11216.
49. Maurice T, Mustafa MH, Desrumaux C, Keller E, Naert G, de la CGBM, Rodriguez Cruz Y, Garcia Rodriguez JC (2013) Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ non-transgenic mouse model of Alzheimer’s disease. J Psychopharmacol 27:1044-1057.
50. Miljus N, Heibeck S, Jarrar M, Micke M, Ostrowski D, Ehrenreich H, Heinrich R (2014) Erythropoietin-mediated protection of insect brain neurons involves JAK and STAT but not PI3K transduction pathways. Neuroscience 258:218-227.
51. Millet A, Bouzat P, Trouve-Buisson T, Batandier C, Pernet-Gallay K, Gaide-Chevronnay L, Barbier EL, Debillon T, Fontaine E, Payen JF (2016) Erythropoietin and its derivates modulate mitochondrial dysfunction after diffuse traumatic brain injury. J Neurotrauma 33:1625-1633.
52. Montesino R, Toledo JR, Sanchez O, Sanchez A, Harvey DJ, Royle L, Dwek RA, Rudd PM, Gerwig GJ, Kamerling JP, Cremata JA (2008) Monosialylated biantennary N-glycoforms containing GalNAc-Glc-NAc antennae predominate when human EPO is expressed in goat milk. Arch Biochem Biophys 470:163-175.
53. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI (2006) Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316:999-1005.
54. Morimoto K, Tsuda E, Said AA, Uchida E, Hatakeyama S, Ueda M, Hayakawa T (1996) Biological and physicochemical characterization of recombinant human erythropoietins fractionated by Mono Q column chromatography and their modification with sialyltransferase. Glycoconj J 13:1013-1020.
55. Nagańska E, Taraszewska A, Matyja E, Grieb P, Rafalowska J (2010) Neuroprotective effect of erythropoietin in amyotrophic lateral sclerosis (ALS) model in vitro. Ultrastructural study. Folia Neuropathol 48:35-44.
56. Noh MY, Cho KA, Kim H, Kim SM, Kim SH (2014) Erythropoietin modulates the immune-inflammatory response of a SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). Neurosci Lett 574:53-58.
57. Ott C, Martens H, Hassouna I, Oliveira B, Erck C, Zafeiriou MP, Peteri UK, Hesse D, Gerhart S, Altas B, Kolbow T, Stadler H, Kawabe H, Zimmermann WH, Nave KA, Schulz-Schaeffer W, Jahn O, Ehrenreich H (2015) Widespread expression of erythropoietin receptor in brain and its induction by injury. Mol Med doi: 10.2119/ molmed.2015.00192.
58. Pankratova S, Kiryushko D, Sonn K, Soroka V, Kohler LB, Rathje M, Gu B, Gotfryd K, Clausen O, Zharkovsky A, Bock E, Berezin V (2010) Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain 133:2281-2294.
59. Park KH, Choi NY, Koh SH, Park HH, Kim YS, Kim MJ, Lee SJ, Yu HJ, Lee KY, Lee YJ, Kim HT (2011) L-DOPA neurotoxicity is prevented by neuroprotective effects of erythropoietin. Neurotoxicology 32:879-887.
60. Park SS, Park J, Ko J, Chen L, Meriage D, Crouse-Zeineddini J, Wong W, Kerwin BA (2009) Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci 98:1688-1699.
61. Parra AL, Rodriguez JC (2012) Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment. Cent Nerv Syst Agents Med Chem 12:60-68.
62. Pasqualetti G, Brooks DJ, Edison P (2015) The role of neuroinflammation in dementias. Curr Neurol Neurosci Rep 15:17.
63. Ponce LL, Navarro JC, Ahmed O, Robertson CS (2013) Erythropoietin neuroprotection with traumatic brain injury. Pathophysiology 20:31-38.
64. Qin C, Zhou S, Xiao Y, Chen L (2014) Erythropoietin enhances mitochondrial biogenesis in cardiomyocytes exposed to chronic hypoxia through Akt/eNOS signalling pathway. Cell Biol Int 38:335-342.
65. Rabie T, Marti HH (2008) Brain protection by erythropoietin: a manifold task. Physiology (Bethesda) 23:263-274.
66. Ratilal BO, Arroja MM, Rocha JP, Fernandes AM, Barateiro AP, Brites DM, Pinto RM, Sepodes BM, Mota-Filipe HD (2014) Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion. J Neurosurg 121:55-62.
67. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H (2010) Erythropoietin as neuroprotective and neuroregenerative treatment strategy:comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol 24:573-594.
68. Sargin D, El-Kordi A, Agarwal A, Muller M, Wojcik SM, Hassouna I, Sperling S, Nave KA, Ehrenreich H (2011) Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC Biol 9:27.
69. Shang YC, Chong ZZ, Wang S, Maiese K (2012) Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 4:187-201.
70. Shen J, Wu Y, Xu JY, Zhang J, Sinclair SH, Yanoff M, Xu G, Li W, Xu GT (2010) ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci 51:35-46.
71. Siddiqui WA, Ahad A, Ahsan H (2015) The mystery of BCL2 family:Bcl-2 proteins and apoptosis: an update. Arch Toxicol 89:289-317.
72. Sinclair AM (2013) Erythropoiesis stimulating agents: approaches to modulate activity. Biologics 7:161-174.
73. Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M (2006) CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 251:124-128.
74. Su KH, Shyue SK, Kou YR, Ching LC, Chiang AN, Yu YB, Chen CY, Pan CC, Lee TS (2011) β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 226:3330-3339.
75. Toledo JR, Sánchez O, Seguí RM, García G, Montañez M, Zamora PA, Rodríguez MP, Cremata JA (2006) High expression level of recombinant human erythropoietin in the milk of non-transgenic goats. J Biotechnol 123:225-235.
76. Wagner LM, Billups CA, Furman WL, Rao BN, Santana VM (2004) Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 22:1886-1893.
77. Wang R, Wu X, Liang J, Qi Z, Liu X, Min L, Ji X, Luo Y, Zhao H (2015) Intra-artery infusion of recombinant human erythropoietin reduces blood-brain barrier disruption in rats following cerebral ischemia and reperfusion. Int J Neurosci 125:693-702.
78. Wang X, Zhu C, Wang X, Gerwien JG, Schrattenholz A, Sandberg M, Leist M, Blomgren K (2004) The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 91:900-910.
79. Wei L, Han BH, Li Y, Keogh CL, Holtzman DM, Yu SP (2006) Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J Pharmacol Exp Ther 317:109-116.
80. Won HH, Park I, Lee E, Kim JW, Lee D (2009) Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach. BMC Bioinformatics 10 Suppl 1:S53.
81. World Health Organization (2011) World Health Statistics 2011. http:// www.who.int/whosis/whostat/2011/en/.
82. Wu JH, Gao Y, Ren AJ, Zhong M, Liu L (2011) Erythropoietin receptor antibody inhibits oxidative stress induced retinal neovascularization in mice. Int J Ophthalmol 4:243-246.
83. Yu D, Fan Y, Sun X, Yao L, Chai W (2016) Effects of erythropoietin preconditioning on rat cerebral ischemia-reperfusion injury and the GLT-1/GLAST pathway. Exp Ther Med 11:513-518.
84. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ (2005) Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 387:5-10.
85. Zellinger C, Seeger N, Hadamitzky M, Fischborn S, Russmann V, Wendt H, Pankratova S, Bock E, Berezin V, Potschka H (2011) Impact of the erythropoietin-derived peptide mimetic Epotris on the histopathological consequences of status epilepticus. Epilepsy Res 96:241-249.
86. Zhang G, Lehmann HC, Bogdanova N, Gao T, Zhang J, Sheikh KA (2011) Erythropoietin enhances nerve repair in anti-ganglioside antibody- mediated models of immune neuropathy. PLoS One 6:e27067.
87. Zhang J, Wang Q, Xiang H, Xin Y, Chang M, Lu H (2014) Neuroprotection with erythropoietin in preterm and/or low birth weight infants. J Clin Neurosci 21:1283-1287.
88. Zhou TF, Yu JG (2013) Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia. J Surg Res 183:304-312.